Everything below concerns NAD+. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-01-23. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
| Property | Value | Notes |
|---|---|---|
| Systematic class | Pyridine nucleotide | Contains nicotinamide, ribose, and phosphate |
| Common form | beta-NMN | Anomeric configuration relevant to enzyme recognition |
| Molecular formula | C11H15N2O8P | As the free acid |
| Molar mass | 334.22 g/mol | Calculated for the free acid |
| CAS Registry Number | 1094-61-7 | Commonly associated with beta-D-NMN |
NMN is present in small amounts in some foods, including certain vegetables, fruits, and animal products, but food content varies widely and is not well standardized. In laboratory research, NMN is used as a tool compound to study NAD+ metabolism, mitochondrial function, and cellular stress responses. Animal studies have reported changes in NAD+ levels and various physiological measures after NMN administration, but species differences and study designs limit direct extrapolation to humans. Human trials have largely focused on safety, tolerability, and pharmacokinetics, with fewer studies examining clinical endpoints.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
=== Epsilon (ε) opioid receptor === Another postulated opioid receptor is the ε opioid receptor. The existence of this receptor was suspected after the endogenous opioid peptide beta-endorphin was shown to produce additional actions that did not seem to be mediated through any of the known opioid receptors. Activation of this receptor produces strong analgesia and release of met-enkephalin; a number of widely used opioid agonists, such as the μ agonist etorphine and the κ agonist bremazocine, have been shown to act as agonists for this effect (even in the presence of antagonists to their more well known targets), while buprenorphine has been shown to act as an epsilon antagonist. Several selective agonists and antagonists are now available for the putative epsilon receptor; however, efforts to locate a gene for this receptor have been unsuccessful, and epsilon-mediated effects were absent in μ/δ/κ "triple knockout" mice, suggesting the epsilon receptor is likely to be either a splice variant derived from alternate post-translational modification, or a heteromer derived from hybridization of two or more of the known opioid receptors.
== Health and safety == Certain blue LEDs and cool-white LEDs can exceed safe limits of the so-called blue-light hazard as defined in eye safety specifications such as "ANSI/IESNA RP-27.1–05: Recommended Practice for Photobiological Safety for Lamp and Lamp Systems". One study showed no evidence of a risk in normal use at domestic illuminance, and that caution is only needed for particular occupational situations or for specific populations. In 2006, the International Electrotechnical Commission published IEC 62471 Photobiological safety of lamps and lamp systems, replacing the application of early laser-oriented standards for classification of LED sources. While LEDs have the advantage over fluorescent lamps, in that they do not contain mercury, they may contain other hazardous metals such as lead and arsenic. In 2016 the American Medical Association (AMA) issued a statement concerning the possible adverse influence of blueish street lighting on the sleep-wake cycle of city-dwellers. Critics in the industry claim exposure levels are not high enough to have a noticeable effect.
==== Dame Commander of the Order of the British Empire (DBE) ==== Civil Dr Margaret Ebunoluwa Aderin, , Chancellor, University of Leicester. For services to Science Education and to Diversity. Amanda Jayne Blanc, Group Chief Executive Officer, Aviva. For services to Business, to Gender Equality and to Net-Zero. Professor Sonia Boyce, , Artist. For services to Art. Jilly Cooper, , Author. For services to Literature and to Charity. Felicity Ann Dahl, Founder, Roald Dahl's Marvellous Children's Charity and the Roald Dahl Museum and Story Centre. For services to Philanthropy, to Literature and to Young People. Dr Jennifer Dixon, , Chief Executive, The Health Foundation. For services to the NHS and to Public Health. Tristina Adele Harrison, Chief Executive Officer, TalkTalk Group. For services to Telecommunications. Dianne Michèle Jeffrey, , lately Trustee and Founder Chair, Age International. For services to Older People Abroad and to the community in Derbyshire. Professor Valerie Joan Lund, , Emeritus Professor in Rhinology, University College London. For services to Rhinology. Siobhain Ann McDonagh, , Member of Parliament for Mitcham and Morden. For Parliamentary and Political Service. Ruth Elizabeth Miskin, , Children's Reading Expert, Read Write Inc. For services to Education. Marit Mohn, Philanthropist. For services to Philanthropy. Professor Molly Morag Stevens, , John Black Professor of Bionanoscience, University of Oxford and Professor, Imperial College London. For services to Medicine.
The Clinical Laboratory Improvement Amendments (CLIA) of 1988 are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, except clinical trials and basic research.
Sources: en.wikipedia.org
Decreased appetite Sleep disorder Confusional state Restlessness Libido decreased (including loss of libido) Somnolence Tremor Disturbance in attention Paraesthesia Hypoaesthesia Tachycardia Palpitations Vomiting Dry mouth Diarrhea Hyperhidrosis Muscle spasms Fatigue Asthenia Malaise Feeling abnormal Weight decreased The majority of these reactions were mild or moderate, associated with treatment initiation, and of short duration.
Reticular (linear) pattern (sometimes called "reticulonodular" because of the appearance of nodules at the intersection of the lines, even though there are no true nodules present) idiopathic pulmonary fibrosis connective tissue disease sarcoidosis radiation fibrosis asbestosis lymphangitis carcinomatosa PCP Nodular pattern
This increase in calcium within the cell then activates a sodium-calcium exchanger (NCX). The sodium-calcium exchanger removes one Ca2+ from the cell and introduces three Na+ into the cell. This exchange further increases the membrane potential. Calcium later reenters the cell via SERCA and calcium channels located on the cell membrane. The increase in membrane potential produced by these mechanisms, activates T-type calcium channels and then L-type calcium channels (which open very slowly). These channels allow a flow of Ca2+ into the cell, making the membrane potential even more positive. Phase 0 This is the depolarization phase. When the membrane potential reaches the threshold potential (around -20 to -50 mV), the cell begins to rapidly depolarise (become more positive). This is mainly due to the flow of Ca2+ through L-type calcium channels, which are now fully open. During this stage, T-type calcium channels and HCN channels deactivate. Phase 3 This phase is the repolarization phase. This occurs due to the inactivation of L-type calcium channels (preventing the movement of Ca2+ into the cell) and the activation of potassium channels, which allows the flow of K+ out of the cell, making the membrane potential more negative.
They are either commercially available or easily synthesized, They have high acidity (pKa ~ 4) allowing for facile in situ deprotonation, The metal-carboxylate bond formation is reversible, facilitating the formation of well-ordered crystalline MOFs, and The bridging bidentate coordination ability of carboxylate groups favors the high degree of framework connectivity and strong metal-ligand bonds necessary to maintain MOF architecture under the conditions required to evacuate the solvent from the pores. The most common transition metals employed in carboxylate-based frameworks are Cu2+ and Zn2+. Lighter main-group metal ions have also been explored. Be12(OH)12(btb)4, the first successfully synthesized and structurally characterized MOF consisting of a light main group metal ion, shows high hydrogen storage capacity, but it is too toxic to be employed practically. There is considerable effort being put forth in developing MOFs composed of other light main group metal ions, such as magnesium in Mg4(bdc)3. The following is a list of several MOFs that are considered to have the best properties for hydrogen storage as of May 2012 (in order of decreasing hydrogen storage capacity). While each MOF described has its advantages, none of these MOFs reach all of the standards set by the U.S. DOE. Therefore, it is not yet known whether materials with high surface areas, small pores, or di- or trivalent metal clusters produce the most favorable MOFs for hydrogen storage.
It could also reflect steric and chemical properties that had another effect on the codon during its evolution. Amino acids with similar physical properties also tend to have similar codons, reducing the problems caused by point mutations and mistranslations. Three main hypotheses address the origin of the genetic code. Many models belong to one of them or to a hybrid:
Sources: en.wikipedia.org
NMN stands for nicotinamide mononucleotide. It is a naturally occurring nucleotide intermediate in NAD+ biosynthesis.
NMN is a direct precursor in the salvage pathway that produces NAD+. Enzymes called NMN adenylyltransferases convert NMN into NAD+, a coenzyme involved in redox reactions and signaling.
No. Nicotinamide riboside is a related compound that lacks the phosphate group present in NMN. Both can influence NAD+ pathways, but their structures, transport, and metabolism differ.
NMN is nicotinamide mononucleotide, a nucleotide intermediate in NAD+ biosynthesis. It occurs naturally in cells and is also produced commercially as a supplement ingredient.